Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide vs sitagliptin in type 2 diabetes mellitus with renal impairment
2010-019777-15Phase 3Completed
- Sponsor
- GSK
- Start
- May 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of albiglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Change in HbA1c from baseline at week 26. Started May 2010; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-019777-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019777-15.